At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,054 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in Denmark
In Brief
An observational study for Breast Cancer. Completed, enrolled 1,054 participants across 1 site.
Detailed Summary
The objective is to retrospectively describe and assess clinical and demographical characteristics, treatment patterns in a real-world (RW) setting of patients with HR+/HER2- (hormone receptor positive/human epidermal growth factor receptor 2 negative) locally advanced or metastatic breast cancer receiving palbociclib in combination treatment
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesDenmark
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartFeb 2022
First PostedJul 2022
Primary CompletionAug 2022
TodayJul 2026
First PostedJul 11, 2022
Enrollment StartFeb 1, 2022
Primary CompletionAug 1, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.0 years ago